Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1

Abstract

Remodeling tumor immune microenvironment (TIME) is an important strategy to lift the immunosuppression and achieve immune normalization. In this work, a mannosylated lactoferrin nanoparticulate system (Man-LF NPs) is developed for dual-targeting biomimetic codelivery of shikonin and JQ1 via the mannose receptor and LRP-1 that are overexpressed in both cancer cells and tumor-associated macrophages. The Man-LF NPs can serve as multitarget therapy for inducing immune cell death in the cancer cells, repressing glucose metabolism and repolarizing tumorassociated macrophages, and consequently, lead to remodeling the TIME (e.g., promotion of dendritic cell maturation and CD8 + T cell infiltration, as well as suppression of Treg). Moreover, JQ1 is a suppressor of PD-L1, and the Man-LF NPs can also work on PD-L1 checkpoint blockage. The results reveal the synergistic combination of shikonin and JQ1 and the treatment potency of the Man-LF NPs. Importantly, it is demonstrated that the interaction between the tumor metabolism and immunity plays an essential role in immunotherapy, and the developed drug combination and nanoformulation can target the multiple components in the complicated network of TIME, providing a potential therapeutic strategy.

Nanoparticles Loaded with the BET Inhibitor JQ1 Block the Growth of Triple Negative Breast Cancer Cells In Vitro and In Vivo

“…Furthermore, the possibility of co-encapsulation of other active compounds offered by this kind of nanoparticles may represent an additional advancement of the anticancer features of this nanoformulation. Indeed, the recent direction of the research of anticancer use of BET inhibitors suggests the use of combinations with other chemotherapeutics, including associations inside the same delivery biosystems [9,22,38,41,42].…”

Reprogramming Tumor Associated Macrophages toward M1 Phenotypes with Nanomedicine for Anticancer Immunotherapy

“…Huang and co‐workers designed a mannosylated lactoferrin nanoparticle loading shikonin and JQ1 (a bromodomain inhibitor of PD‐L1) to target cancer cells and TAMs via specific interactions with mannose receptors and low‐density lipoprotein receptor‐related protein 1 (LRP‐1) on TAMs surface. [ 70 ] The dual targeting lactoferrin nanoparticles could effectively induce ICD in cancer cells, downregulate lactic acid production and result in a 1.5‐fold increase of M1/M2 ratio in tumor with upregulated expression of STAT1 and TNF‐α. Consequently, the lactoferrin nanoparticles activated the antitumor immunity with promoted DC maturation, increased infiltration of CD8+ T cells and reduced PD‐L1 expression, thereby exhibiting a synergistic therapy on the tumor growth of CT26 colon tumor model.…”

GSH depletion liposome adjuvant for augmenting the photothermal immunotherapy of breast cancer

“…The immunosuppressive TME promotes cancer cell growth and forms a heavy barrier to hinder cancer diagnosis and therapy (3), including inhibiting immunogenic cell death (ICD) induction of tumor cells, inhibiting dendritic cells (DCs) maturation, and cytotoxic T cell response (4). Fortunately, with decades of efforts on exploration of the TME, some distinctive hallmarks are gradually clear to the researches, bringing opportunities to remodel the TME by up-regulating the benefit part and down-regulating the unprofitable factors to amplify cancer theranostic efficacy (5)(6)(7).…”